Dateline: NEW YORK, December 13, 2024 – Waters Corporation (WAT) raised the lower end of its 2025 profit forecast Monday after stronger-than-expected second-quarter results driven by resilient lab equipment demand 1.
The guidance increase signals improving fundamentals in the analytical instruments sector, potentially benefiting investors as pharmaceutical and biotech spending recovers.
- Waters lifts 2025 revenue growth guidance to 5-7%
- Q3 adjusted EPS expected $3.15-$3.25 range
- Lab equipment demand shows resilient recovery trends
Market reaction & context
The Milford, Massachusetts-based lab equipment maker now expects 2025 revenue growth in the range of 5% to 7%, compared with previous projections 2. Waters’ improved outlook contrasts with mixed performance across the broader life sciences tools sector, where companies like Thermo Fisher Scientific have faced varying demand patterns.
For the third quarter, Waters expects adjusted profit per share between $3.15 and $3.25, compared with analysts’ average expectations of $3.23 3. The company’s updated full-year sales growth guidance represents an increase from earlier projections, according to market reports.
Detailed analysis
Waters’ forecast revision reflects improved demand across its core analytical instruments and services segments. The company specializes in high-performance liquid chromatography systems and mass spectrometry equipment used in pharmaceutical research, environmental testing, and food safety applications.
The better-than-expected second-quarter results that prompted the guidance raise suggest pharmaceutical and biotechnology customers are increasing capital expenditures after a period of reduced spending. This trend could indicate broader recovery in life sciences research funding.
Outlook & industry context
Waters’ performance stands out in the analytical instruments sector, where demand has been pressured by pharmaceutical industry consolidation and reduced research budgets. The company’s specialized focus on chromatography and mass spectrometry positions it to benefit from increasing regulatory requirements and drug development activities.
Industry analysts view Waters as a bellwether for life sciences capital equipment spending, making its improved guidance a positive signal for the broader sector. The company’s recurring revenue from service contracts and consumables provides stability during equipment spending cycles.
Investment implications
Waters’ raised guidance suggests the analytical instruments market may be stabilizing after recent headwinds. The company’s ability to exceed expectations while many peers face challenges highlights its competitive positioning in specialized laboratory technologies.
Investors should monitor whether Waters can sustain this momentum through 2025, particularly as pharmaceutical companies continue adjusting research and development priorities. The guidance increase provides near-term confidence but execution will be key.
Not investment advice. For informational purposes only.
References
1 “Waters raises lower end of 2025 profit forecast on demand for lab equipment”. Yahoo Finance. Retrieved December 13, 2024.
2 “Waters raises 2025 profit forecast on resilient demand for lab equipment”. MSN Money. Retrieved December 13, 2024.
3 “Waters raises lower end of 2025 profit forecast on demand for lab equipment”. SEPE. Retrieved December 13, 2024.
4 Waters Corp. Reuters. Retrieved December 13, 2024.
5 “The Lab Equipment Giant That’s Outperforming All Odds: Waters Corporation”. AI Invest. Retrieved December 13, 2024.
6 Waters (WAT) Stock Latest News. Finance Charts. Retrieved December 13, 2024.